Cell Signaling Technology Logo - Extra Large
View Featured Offers >>
  1. Products /
  2. Primary Antibodies /
  3. Fatty Acid and Lipid Metabolism Antibody Sampler Kit II

Fatty Acid and Lipid Metabolism Antibody Sampler Kit II #99729

    Product Information

    Kit Usage Information

    Protocols

    Product Description

    The Fatty Acid and Lipid Metabolism Antibody Sampler Kit II provides an economical means of detecting select components involved in fatty acid and lipid metabolism. The kit includes enough antibodies to perform two western blot experiments with each primary antibody.

    Background

    Sterol regulatory element–binding proteins (SREBPs) are basic helix-loop-helix–leucine zipper (bHLH-Zip) transcription factors (1,2). Studies show that SREBP-1-dependent fatty acid homeostasis has a critical role in promoting the pro-tumor phenotype of M2-like tumor-associated macrophages (TAMs), and inhibition of SREBP-1 enhances the efficacy of immune checkpoint blockade (3). In addition, statin-induced suppression of cholesterol biosynthesis stimulates SREBP-1 activation and, consequently, induces TGF-β signaling, promoting the epithelial-to-mesenchymal transition in pancreatic ductal adenocarcinoma (4).

    ATP-citrate lyase (ACL) is a homotetramer that catalyzes the formation of acetyl-coenzyme A (CoA) and oxaloacetate (OAA) in the cytosol, which is the key step for the biosynthesis of fatty acids, cholesterol, and acetylcholine, as well as for gluconeogenesis (5). Phosphorylation of ACL at Ser455 abolishes the homotropic allosteric regulation by citrate and enhances the catalytic activity of the enzyme (6).

    Fatty acid synthase (FASN) catalyzes the synthesis of long-chain fatty acids from acetyl-CoA and malonyl-CoA. FASN is active as a homodimer with seven different catalytic activities and produces lipids in the liver for export to metabolically active tissues or storage in adipose tissue (7).

    Acetyl-CoA carboxylase (ACC) catalyzes the pivotal step of the fatty acid synthesis pathway. Phosphorylation by AMPK at Ser79 or by PKA at Ser1200 inhibits the enzymatic activity of ACC (8).

    Stearoyl-CoA desaturase 1 (SCD1) is a key lipogenic enzyme found in the endoplasmic reticulum that catalyzes the conversion of palmitoyl–CoA and stearoyl–CoA to palmitoleoyl–CoA (16:1) and oleoyl–CoA (18:1) (1-3). Palmitoleate and oleate are the major components of triglycerides, membrane phospholipids, and cholesterol esters (9).

    Diacylglycerol O-acyltransferase 1 (DGAT1) catalyzes triacylglycerol biosynthesis from diacylglycerol and fatty acyl-CoA (10). Studies show that DGAT1 is highly expressed in glioblastoma (GBM), stimulating the storage of excess fatty acids in triacylglycerols and lipid droplets to block GBM cells from oxidative damage. DGAT1 inhibition in GBM cells enhances reactive oxygen species (ROS) production and causes mitochondrial damage, leading to cancer cell death (11). In addition, Jumonji domain-containing 6 (JMJD6) is critical for clear cell renal cell carcinoma (ccRCC) development. JMJD6, along with RBM39, promotes DGAT1 expression. DGAT1 inhibition suppresses ccRCC tumorigenesis in vivo (12).

    Acyl-CoA synthetase long-chain family member 4 (ACSL4) preferentially catalyzes the formation of arachidonoyl-CoA (AA-CoA) by inserting CoA into arachidonic acid (AA) (13). ACSL4-catalyzed acyl-CoAs also participate in the regulation of steroidogenesis (14), eicosanoid biosynthesis (15), and phospholipid remodeling (16). ACSL4 is an essential enzyme for the conversion of two key ferroptosis-inducing signals, oxidized arachidonic and adrenic phosphatidylethanolamines (17,18). Genome-wide CRISPR/Cas9-based genetic screens have demonstrated that ACSL4 is an essential component for ferroptosis execution (18), and genetic or pharmacological inhibition of ACSL4 can initiate a specific anti-ferroptotic rescue pathway (17). ACSL4 expression is upregulated in ferroptosis-sensitive cancer cells compared with ferroptosis-resistant cells (19). It has been shown to predict sensitivity to ferroptosis in a panel of basal-like breast cancer cell lines (18). Moreover, high ACSL4 protein expression in hepatocellular carcinoma (HCC) clinical tissue specimens is associated with improved patient outcomes after sorafenib treatment and could serve as a predictive biomarker (20).
    1. Brown, M.S. and Goldstein, J.L. (1997) Cell 89, 331-40.
    2. Horton, J.D. et al. (2002) J Clin Invest 109, 1125-31.
    3. Liu, C. et al. (2019) Immunity 51, 381-397.e6.
    4. Gabitova-Cornell, L. et al. (2020) Cancer Cell 38, 567-583.e11.
    5. Towle, H.C. et al. (1997) Annu Rev Nutr 17, 405-33.
    6. Potapova, I.A. et al. (2000) Biochemistry 39, 1169-79.
    7. Katsurada, A. et al. (1990) Eur J Biochem 190, 427-33.
    8. Ha, J. et al. (1994) J Biol Chem 269, 22162-8.
    9. Ntambi, J.M. et al. (2002) Proc Natl Acad Sci USA 99, 11482-6.
    10. McLelland, G.L. et al. (2023) Nature 621, 171-178.
    11. Cheng, X. et al. (2020) Cell Metab 32, 229-242.e8.
    12. Zhou, J. et al. (2022) Mol Cell 82, 3030-3044.e8.
    13. Quan, J. et al. (2021) Eur J Pharmacol 909, 174397.
    14. Cornejo Maciel, F. et al. (2005) J Mol Endocrinol 34, 655-66.
    15. Kuwata, H. et al. (2014) Biochim Biophys Acta 1841, 44-53.
    16. Killion, E.A. et al. (2018) Mol Metab 9, 43-56.
    17. Kagan, V.E. et al. (2017) Nat Chem Biol 13, 81-90.
    18. Doll, S. et al. (2017) Nat Chem Biol 13, 91-98.
    19. Yuan, H. et al. (2016) Biochem Biophys Res Commun 478, 1338-43.
    20. Feng, J. et al. (2021) Acta Pharmacol Sin 42, 160-170.

    Database Links

    UniProt ID: Q13085 , O00763 , P53396 , P49327 , O00767 , P36956 , O60488 , O75907


    Entrez-Gene Id: 31 , 32 , 47 , 2194 , 6319 , 6720 , 2182 , 8694


    Limited Uses

    Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

    Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.

    For Research Use Only. Not for Use in Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    U.S. Patent No. 7,429,487, foreign equivalents, and child patents deriving therefrom.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.